Li Long
Corporate Officer/Principal bei KEZAR LIFE SCIENCES, INC.
Profil
Li Long is currently working as Vice President-Immunology Clinical Development at Kezar Life Sciences, Inc. Prior to this, Dr. Long worked as Senior Director-Clinical Development at Principia Biopharma, Inc. Dr. Long holds a doctorate degree from McGill University.
Aktive Positionen von Li Long
| Unternehmen | Position | Beginn |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Li Long
| Unternehmen | Position | Ende |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | - |
Ausbildung von Li Long
| McGill University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
